Objective: Accumulating data have demonstrated that macrolide antibiotics suppress Pseudomonas aeruginosa virulence, which may explain the efficacy of macrolides in clinical settings. We examined the virulence of macrolide-treated bacteria in vivo. Methods: P. aeruginosa PAO-1 was grown for 24 h on agar containing sub-MIC antibiotics, and then mice were challenged intranasally with 10 7 cfu of bacteria.
Introduction
Pseudomonas aeruginosa is one of the most important bacterial pathogens in chronic pulmonary diseases, such as cystic fibrosis [1] [2] [3] and diffuse panbronchiolitis. 4 Once P. aeruginosa colonizes the airway mucosa in patients, it is difficult to eradicate it despite treatment with potent antibiotics. Since infection by P. aeruginosa usually leads to death due to respiratory failure or other consequences of respiratory infection, it is extremely important to inhibit colonization or attempt to eradicate the bacteria.
Certain macrolide antibiotics, such as erythromycin (ERY), clarithromycin (CLR) and azithromycin (AZM), have been reported to improve the clinical symptoms and prognosis of patients with chronic P. aeruginosa infections when these antibiotics are administered for prolonged periods, i.e. several months to years. [5] [6] [7] [8] [9] Since at therapeutic doses these macrolides are not regarded as effective against P. aeruginosa, many investigators are interested in the mechanisms of the clinical efficacy of these antibiotics. On the one hand there is a large body of evidence that macrolide antibiotics modulate the host defence mechanisms; [10] [11] [12] [13] various groups have shown that macrolides suppress the virulence of some bacteria by inhibiting the production of toxins, for example. 6, [14] [15] [16] P. aeruginosa produces several exotoxins, including exotoxin A, protease and elastase, during the course of infection, which are of key importance in the pathogenesis of the disease caused by this bacterium. 17, 18 We, and others, have reported that some macrolide antibiotics at sub-MICs inhibit the production of P. aeruginosa exotoxins. 6, 14, 15, 19 In addition, we have reported that sub-MICs of macrolide antibiotics enhance the susceptibility of P. aeruginosa to serum bactericidal activity by altering cell surface structures, lipopolysaccharide (LPS) and outer membrane proteins. 20, 21 These data indicate that bacteria exposed to macrolide antibiotics may induce different responses.
In the present study, we examined host responses in the lungs of mice following exposure to antibiotic-treated P. aeruginosa. Paradoxically, our data demonstrated that CLR-, ERY-and AZM-treated bacteria were more virulent than non-treated bacteria or bacteria treated with other antibiotics. Lethality rate correlated well with the degree of host response, such as increase in tumour necrosis factor-α (TNF-α), nitric oxide (NO), elastase and permeability in the lungs.
Materials and methods

P. aeruginosa strains
P. aeruginosa PAO-1 was kindly provided by Dr B. H. Iglewski (University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA). Eight clinical isolates of P. aeruginosa (Nagasaki University Hospital, Nagasaki, Japan) were used in some experiments. 22 Four strains were isolated from blood, and others were isolated from sputum.
Animals
Six-week-old male ICR mice were purchased from Charles River Japan (Kanagawa, Japan). The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Toho University School of Medicine.
Antimicrobial agents
The following antimicrobial agents were kindly provided by their manufacturers: ERY (Dainippon Pharmaceutical Co., Ltd, Osaka, Japan), CLR (Taisho Pharmaceutical Co., Ltd, Tokyo, Japan), AZM (Pfizer Laboratories, Groton, CT, USA), oleandomycin (OM) (Pfizer Laboratories), josamycin (JM) (Yamanouchi Pharmaceutical Co., Ltd, Tokyo, Japan), ceftazidime (CAZ) (Tanabe Pharmaceutical Co., Ltd, Osaka, Japan), minocycline (MIN) (Wyeth Lederle Japan, Ltd, Tokyo, Japan), tobramycin (TOB) (Shionogi Pharmaceutical Co., Ltd, Osaka, Japan), clindamycin (CLI) (Japan Upjohn Co., Ltd, Tokyo, Japan) and ofloxacin (OFX) (Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan). 
Pretreatment of P. aeruginosa with sub-MIC antibiotics
(10 mg/L) and OFX (0.1 mg/L). 23 To examine concentration dependence, AZM at concentrations of 1.25, 2.5 and 5 mg/L was selected. After incubation on agar containing sub-MICs of antibiotics, bacteria were suspended in 0.9% saline to the desired cell density, which was confirmed by plating on to Mueller-Hinton agar after serial 10-fold dilutions.
Inoculation of P. aeruginosa into the lungs
Mice were anaesthetized lightly by intramuscular injection of a mixture of 60 mg/kg ketamine (Sankyo Pharmaceutical, Tokyo, Japan) and 10 mg/kg xylazine (Bayer Japan, Tokyo, Japan) and challenged intranasally with a bacterial suspension containing c. 10 7 cfu of organisms. Each experiment was repeated at least twice. Survival of mice was recorded 3, 6, 9, 24 and 48 h after challenge with the bacteria.
Collection of bronchoalveolar lavage fluid (BALF)
Mice were killed by inhalation of ether at the indicated time points. Bronchoalveolar lavage (BAL) was carried out by instilling 1 mL of 0.9% saline through the tracheal cannula, and BAL fluid (BALF) was centrifuged at 10 000g for 5 min.
Supernatants were stored at -80°C until assayed.
Measurement of pulmonary permeability
Total protein concentration in BALF was measured to examine changes in pulmonary permeability after inoculation of bacteria or bacterial toxins. BALF was mixed with Bio-Rad solution (Bio-Rad Laboratories, Richmond, CA, USA) and incubated at room temperature for 10 min. The absorbance of the fluid was then read at 595 nm on a spectrophotometer. The protein concentration was determined by comparison with the standard curve using bovine serum albumin.
Histopathological examination of the lungs
Mice challenged with antibiotic-treated P. aeruginosa were killed by inhalation of ether at the indicated time points, and the lungs removed. The lungs were fixed in 10% formalin, embedded in paraffin wax, sectioned, and then stained with haematoxylin-eosin. The wet weight of the lungs was determined before fixation in some experiments.
TNF-α and NO assays
TNF-α levels in BALF were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Biosource International, Inc., Camarillo, CA, USA), according to the manufacturer's instructions. NO generated in BALF was determined by spectrophotometry using a commercially available kit (Assay Designs, Inc., Ann Arbor, MI, USA).
Elastase assay
Elastase activity in BALF was measured as described previously. 22 Briefly, 0.1 mL of BALF supernatant was diluted three-fold with 10 mM Tris (pH 7.5), and added to 2 mg of elastin congo red (Sigma) as a substrate. The mixture was incubated at 37°C for 1 h, with vigorous shaking. The undissolved substrate was removed by centrifugation at 3000g for 10 min. OD 495 values of the supernatants were then compared with a standard curve prepared by treating the substrate for the same period with purified P. aeruginosa elastase (Elastin Products Co., Inc., Owensville, MS, USA) at enzyme concentrations of 0.75-100 mg/L.
Statistical analysis
Student's t-test was used to compare means, and P < 0.05 was considered to be significant.
Results
Mortality rate of mice challenged with P. aeruginosa grown in the presence of sub-MICs of antibiotics
Interestingly, among the antibiotics examined, bacteria treated with macrolide antibiotics (CLR, ERY and AZM) induced the highest mortality rates (80%, 80% and 100%, respectively) ( Figure 1 ). For AZM-treated bacteria, the mortality rate of mice increased from 10% (when challenged with bacteria treated with 1.25 mg/L antibiotic) to 100% (when challenged with bacteria treated with 5 mg/L). In contrast, none of the mice challenged with untreated bacteria (control bacteria) or bacteria treated with other antibiotics, namely OM, JM, CLI, TOB, OFX, CAZ and MIN, died. These data indicate that the increase in lethality of antibiotic-treated bacteria may be specifically induced by some macrolide antibiotics, such as CLR, ERY and AZM.
Changes in the number of bacteria in the lungs
Since in the lethality experiments the first mouse death was observed 6 h after inoculation and more than half of the mice died within 9 h, the results indicated acute toxic effects rather than multiplication of bacteria in the lungs. Thus, we examined the number of bacteria in the lungs of mice challenged with control bacteria and CLR-treated bacteria (Figure 2 ). More than a 10-fold reduction in pulmonary bacterial burden was demonstrated 6 h after challenge of control bacteria, whereas CLR-treated bacteria were not cleared at all. These data indicate that the macrolide-treated bacteria induce certain toxic host responses, which result in death of mice within 48 h after inoculation of bacteria.
Histopathological examination
Twenty-four hours after the challenge with CLR-treated bacteria the lungs of mice demonstrated influx of numerous inflammatory cells, intra-alveolar exudation and haemorrhagic changes in interstitial and alveolar spaces (Figure 3 ). The lungs of mice challenged with control bacteria also showed accumulation of many inflammatory cells, but only a few erythrocytes were observed in extra-vascular spaces.
Wet lung weight and total protein in BALF of mice challenged with bacteria
To characterize acute host responses induced by macrolidetreated bacteria in the lungs, we determined the wet weight of lungs and the total protein content in BALF to measure pulmonary permeability. In both the control and CLR-treated bacteria, lung weight began to increase 3 h after inoculation of bacteria and reached a plateau at 6 h ( Figure 4a ). However, that of the lungs of mice inoculated with CLR-treated bacteria was significantly higher compared with the control group. Correlated with these data, Figure 4b shows higher protein levels in BALF of mice inoculated with CLR-treated bacteria compared with control bacteria, between 3 and 9 h. Taken together, these data demonstrate that CLR-treated P. aeruginosa induced a drastic increase in pulmonary permeability compared with control bacteria.
Total protein in BALF of mice challenged with several clinical isolates
To examine whether these phenomena were specific to P. aeruginosa PAO-1 or were common to different clinical isolates, we investigated the total protein content in BALF from mice inoculated with eight clinical isolates, which were grown in the presence or absence of sub-MICs of CLR ( Figure 5 ). Although the extent of the increase in protein concentration differed among the strains tested, it was usually higher in the case of CLR-treated bacteria, except for one strain. These data demonstrate that CLR, at sub-MICs, may enhance the pulmonary permeability-inducing activity of a large number of clinical isolates of P. aeruginosa. Although we examined eight strains that produce from large to small elastase concentrations (0.6-92.75 mg/L), 22 the total protein content in BALF from mice did not have a certain relationship to elastase production in each strain of P. aeruginosa after inoculation of macrolide-treated organisms.
TNF-α and NO in BALF
To understand better the mechanisms involved in the increase in pulmonary permeability induced by CLR-treated bacteria, we examined the levels of TNF-α and NO in BALF of mice inoculated with non-treated and CLR-treated bacteria. We observed significantly higher levels of TNF-α at 3 h in BALF of mice challenged with CLR-treated bacteria, although there was no difference at subsequent time points (Figure 6a ). In contrast, significantly higher levels of NO were demonstrated in BALF of those mice during the whole experimental period (Figure 6b ).
Elastase activity in BALF of mice
The data clearly showed significantly higher levels of elastase in BALF of mice challenged with CLR-treated bacteria during these experimental periods ( Figure 7 ). In mice challenged with control bacteria, no detectable levels of elastase were demonstrated at 3 h, whereas >20 mg/L elastase was demonstrated in BALF from mice challenged with CLRtreated bacteria at this time point. Moreover, c. three-fold higher amounts of elastase were detected at 6 h in this group compared with mice challenged with control bacteria. Interestingly, the kinetic changes of elastase in the control and CLRtreated groups were quite similar to those in protein levels of BALF (Figure 4b ). Taken together, these data indicate overproduction of elastase in mice lungs, which may be associated with elevation of pulmonary permeability in mice challenged with macrolide-treated bacteria.
Discussion
At the beginning of these experiments, we expected that virulence of macrolide-treated bacteria in this model would be attenuated, because data from other studies have demonstrated that macrolide antibiotics suppress the expression of substances that contribute to the virulence of P. aeruginosa, such as exoenzymes, 6, 14, 15, 19 exopolysaccharide 24,25 and pigment. 16 In vitro inhibition of P. aeruginosa exoenzymes by macrolides is a quite consistent observation, although the degrees of suppression depend on experimental conditions, such as antibiotic concentration, incubation time and strains used. Sakata et al. 19 observed >50% reduction of P. aeruginosa elastase in 14 of 34 clinical isolates in the presence of 4 mg/L ERY. Clinically, some macrolide antibiotics, such as ERY, CLR and AZM, have been reported to improve the clinical symptoms and prognosis of patients with chronic P. aeruginosa infections. 5,7-9 Our findings, however, demonstrate that macrolide-treated bacteria are more virulent and induce strong host responses in the lungs. Importantly, more than half of the mice died within 9 h after challenge with bacteria, suggesting involvement of acute toxic effects rather than multiplication of bacteria. In fact, no increase in bacterial burden was observed in the lungs of mice challenged with CLR-treated bacteria. In addition, we observed higher levels of NO between 3 and 9 h and TNF-α at 3 h in BALF of mice inoculated with CLR-treated bacteria. Excessive production of these factors seems to be related directly to toxic reactions, such as hypotension and shock. 26, 27 Production of NO is up-regulated by a variety of stimuli, including pro-inflammatory cytokines (TNF-α, interleukin-1 and interferon-γ) and bacterial components (LPS and lipoteichoic acid). 28, 29 The larger amounts of NO and TNF-α observed in this study may accelerate synergically the changes associated with the inflammatory process, such as microvascular leakage and tissue damage in the lungs. Moreover, a large amount of elastase was detected in mice BALF. Unfortunately, we could not explain why higher amounts of elastase were induced in the lungs of mice challenged with CLR-treated bacteria. We assume that elastase is produced by mice neutrophils or P. aeruginosa. A number of authors have shown that human neutrophil elastase (HNE) is important in the pathophysiology of chronic pseudomonal lung infections. 30, 31 They have shown that both HNE and pseudomonal elastase can disrupt the respiratory epithelium 30 and that HNE is associated with increased protein concentrations in sputum. 31 This may, indeed, be the most likely explanation given the fact that the lung histology from mice infected with macrolide pre-treated organisms shows influx of numerous inflammatory cells. Another possibility is the production of elastase from P. aeruginosa. In the presence of sub-MICs of macrolide antibiotics, the virulence of bacteria may be suppressed, as reported previously. However, it is possible that after these bacteria are introduced into the lungs under antibiotic-free conditions, they might start to produce exoenzymes. Overproduction of elastase may be a reflection of the exoenzyme-suppressing activity of macrolides.
Increase of lethality was demonstrated only in mice challenged with CLR-, ERY-and AZM-treated bacteria, but not with bacteria exposed to the other antibiotics tested. CLR and ERY are 14-membered macrolides, and these share similar structures except for a difference of one side chain residue of the macrolide aglycone ring. In contrast, AZM is a 15-membered macrolide, which differs from ERY by the presence of a nitrogen at position 9a in the macrolide ring.
Specific activities of ERY, CLR and AZM on P. aeruginosa were demonstrated under some experimental conditions. We have reported previously that incubation with ERY, CLR and AZM specifically sensitized the microorganism to serum bactericidal effects. 20, 21 Moreover, these three macrolides, at sub-MICs, were shown to suppress protein synthesis in P. aeruginosa and consequently induce loss of viability over longer incubation periods. 23 On the other hand, we could not observe any change in lethality in mice challenged with bacteria treated with other macrolides (JM, 16-membered; OM, 14-membered) or other classes of antibiotics, including TOB, OFX, CAZ, MIN and CLI. These data indicate that the paradoxical effects on P. aeruginosa may be specific for some macrolide antibiotics. It is likely that the structures of these antibiotics, such as the substitutions on the lactone ring and/or sugar composition, in addition to their simple classification as being 14-, 15-or 16-membered, may be responsible for this activity. In P. aeruginosa strains with various amounts of production of elastase (0.6-92.75 mg/L), 22 the protein concentration in BALF of mice inoculated with CLR-treated bacteria was increased compared with that of mice inoculated with control bacteria ( Figure 5 ). These data show that macrolide pretreated strains other than P. aeruginosa PAO-1 also augment the host inflammatory response. When we administered macrolide antibiotics to mice after inoculation of P. aeruginosa PAO-1, as a model of treatment of pneumonia, the mortality of mice did not increase (data not shown). Our results are not consistent with current dogma, that macrolides reduce production of bacterial virulence factors. Although we speculate that the increase in virulence of macrolide pretreated bacteria may be concerned with direct interaction between bacteria and antibiotics ex vivo, molecular analysis of the macrolide effects on elastase synthesis, such as transcription, translation and secretion processes, may be necessary to understand this phenomenon better. Moreover, how such phenomena are involved in macrolide therapy in a clinical setting, or whether it takes place in the lungs of patients, remains to be clarified in future investigations.
